07 May 2008
A new laser treatment for early vocal-cord cancer has been used to successfully restore patients' voices without radiotherapy or traditional surgery, which can permanently damage vocal quality.
The method has been used in more than 25 patients using a pulsed Potassium-Titanyl-Phosphate (KTP) laser.
"We had previously adapted lasers that target blood vessels to treat precancerous vocal-cord dysplasia and a variety of benign vascular lesions," said Steven Zeitels, director of Massachusetts General Hospital Voice Center.
"We have now applied that experience to treat vocal-cord cancer."
The research team began using pulsed lasers for the treatment of early vocal-cord cancer more than five years ago and successfully treated eight patients with a pulsed-dye laser. The laser uses specific wavelengths of light to target blood vessels.
After initial success the team switched to the more precise pulsed KTP laser, which is even less likely to damage delicate vocal-cord tissue.
The first 22 patients receiving pulsed laser treatment for vocal-cord cancer were found to be cancer-free up to five years after treatment, without removal of vocal-cord tissue or loss of voice quality. Some have required second or third laser treatments to remove residual disease, but another benefit of the therapy is that it does not rule out future therapeutic options.
It is estimated that 90 per cent of patients with early vocal-cord cancer would be candidates for pulsed-KTP laser treatment.
"Currently the optimal angiolytic laser for vocal-cord problems, the pulsed-KTP laser is a critical innovation in the instrumentation arsenal of the laryngeal surgeon," said Mr Zeitels.
"It has greatly enhanced the precision by which we can perform many procedures for chronic laryngeal diseases, both in the operating room, accompanied by the surgical microscope, and in the office."
Click here for EPG Online Physician's tools including disease awareness, diagnosis tools, treatment options and management guidance 
Print Article 
Bookmark
Disease Knowledge Centres feed
-
TRITACE Tablets - 24.72%
... more who have one or more of the following clinical findings: hypertension (systolic blood pressure> 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease ... -
TRITACE Titration Pack - 24.36%
... who have one or more of the following clinical findings: hypertension (systolic blood pressure > 160mmHg or diastolic blood pressure > 90mmHg); high total cholesterol (>5.2 mmol/L); low HDL (<0.9 mmol/L); current smoker; known microalbuminuria; clinical evidence of previous vascular disease. Oral ... -
BETAFERON - 23.54%
... of clinical relapses in ambulatory patients, who have had at least two attacks of neurological dysfunction in the preceding two years followed by complete or incomplete recovery. Secondary progressive multiple sclerosis - Slowing progression of disease and reduction in frequency of clinical relapses ... -
LOCOID Ointment - 22.5%
The product is recommended for clinical use in the treatment of conditions responsive to topical corticosteroids e.g. eczema, dermatitis and psoriasis. Topical corticosteroids are not generally indicated in psoriasis but may be acceptable in psoriasis excluding widespread plaque psoriasis provided ... -
NAGLAZYME Solution for Infusion - 22.5%
... it is of primary importance, especially in severe forms, to initiate treatment as early as possible, before appearance of non-reversible clinical manifestations of the disease. A key issue is to treat young patients aged <5 years suffering from a severe form of the disease, even though patients <5 ... -
ELAPRASE Solution for Infusion - 22.5%
Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials ...
Printed on 09/01/2009 9:22 PM
